Glen Eagle Advisors, LLC Actinium Pharmaceuticals, Inc. Transaction History
Glen Eagle Advisors, LLC
- $650 Billion
- Q2 2025
Shares
3 transactions
Others Institutions Holding ATNM
# of Institutions
61Shares Held
6.77MCall Options Held
39.2KPut Options Held
0-
Black Rock Inc. New York, NY1.88MShares$2.44 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.38MShares$1.8 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny663KShares$862,2490.0% of portfolio
-
Acadian Asset Management LLC Boston, MA490KShares$636,4500.0% of portfolio
-
Geode Capital Management, LLC Boston, MA328KShares$426,9440.0% of portfolio
About Actinium Pharmaceuticals, Inc.
- Ticker ATNM
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 25,184,700
- Market Cap $32.7M
- Description
- Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant (BMT) or a type of cellular therapy, and for other adoptive cell therapies. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly re...